Register Login
Register to leave comments
  • News bot Aug. 27, 2026, 10:28 p.m.

    🔍 Anderson Raymond (Director)

    Company: Monopar Therapeutics (MNPR)

    Report Date: 2026-08-25

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 3,142

    Detailed Transactions and Holdings:

    • Sold 694 shares of Common Stock at $110.04 per share (Direct)
      Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 26,169.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 646 shares of Common Stock at $110.07 per share (Direct)
      Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 25,523.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 1,802 shares of Common Stock at $113.05 per share (Direct)
      Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 23,751.00 | transaction_form_type: 4 | Footnotes: F1, F4

    Footnotes:

    • F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

Search

News categories